11 terminated. 11 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Terminated 11 |
| Phase 2 | 3 | Terminated 3 |
Follow Paralysis: new trials by email Literature Review of Paralysis trials Research Report on Paralysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 40 | 2019-12-17 | 2026-05-22 |
| Diabetic Gastroparesis Study 05 Relamorelin 10 μg - Gastroparesis | Phase 3 | Terminated | Allergan | 202 | 2018-12-20 | 2021-12-15 |
| Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 311 | 2018-02-16 | 2021-08-06 |
| A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 450 | 2018-02-01 | 2021-11-23 |
| A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 467 | 2018-01-24 | 2021-12-22 |
| A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 336 | 2017-09-29 | 2021-07-29 |
| Effects of the Quantity of Repetitive Transcranial Magnetic Stimulation(rTMS) on the Recovery After Stroke repetitive transcranial magnetic stimulation (rTMS) - Stroke, Hemiplegia | Phase 2 / Phase 3 | Terminated | Seoul National University Bundang Hospital | 2 | 2011-01-01 | 2015-05-19 |
| Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Rasagiline, Sugar pill - Progressive Supranuclear Palsy | Phase 3 | Terminated | Prof. Dr. Stefan Lorenzl | 44 | 2010-01-01 | 2013-04-24 |
| Surgery for Vocal Cord Paralysis vocal fold medialization, vocal fold reinnervation - Unilateral Vocal Cord Paralysis | Phase 3 | Terminated | National Institute on Deafness and Other Communication Disorders (NIDCD) | 300 | 2002-10-01 | 2006-04-24 |
| Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) Riluzole - Multiple System Atrophy, Progressive Supranuclear Palsy | Phase 3 | Terminated | King's College London | 800 | 2000-04-01 | 2005-12-15 |
Gastroparesis (5) · Diabetes Mellitus (4) · Hemiplegia (3) · Stroke (3) · Brain Injuries, Traumatic (2) · Muscle Spasticity (2) · Supranuclear Palsy, Progressive (2) · Vomiting (2) · Cerebral Palsy (1) · Cerebrovascular Disorders (1) · Multiple Sclerosis (1) · Multiple System Atrophy (1) · Vocal Cord Paralysis (1)
Neurologic Manifestations (11) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Nervous System Diseases (6) · Brain Diseases (5) · Central Nervous System Diseases (5) · Digestive System Diseases (5) · Gastrointestinal Diseases (5) · Stomach Diseases (5) · Endocrine System Diseases (4) · Glucose Metabolism Disorders (4) · Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Cardiovascular Diseases (3)
relamorelin (5) · Clinical Trials, Phase II as Topic (2) · Clinical Trials, Phase III as Topic (2) · rimabotulinumtoxinB (2) · Riluzole (1) · Sugars (1) · Transcranial Magnetic Stimulation (1) · rasagiline (1)
Allergan (5) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2) · King's College London (1) · National Institute on Deafness and Other Communication Disorders (NIDCD) (1) · Prof. Dr. Stefan Lorenzl (1) · Seoul National University Bundang Hospital (1)
United States (8) · Hungary (6) · Poland (6) · Germany (5) · South Korea (5) · United Kingdom (5) · Argentina (4) · Australia (4) · Austria (4) · Belgium (4) · Brazil (4) · Bulgaria (4) · Canada (4) · Colombia (4) · Denmark (4)
Harvy Schneier (2) · Joseph T Hull, PhD (2) · Nam-Jong Paik, MD, PhD (1) · Peter N Leigh, PhD FRCP (1) · Randal C Paniello, MD (1) · Stefan Lorenzl, PD Dr. (1) · Wieslaw Bochenek (1)
PMID 19029129, PMID 19771175, PMID 21386111, PMID 21829612, PMID 40148033
2017 (3), 2008 (1), 2019 (1)